AstraZeneca Breast Cancer Pill Fails in Key Study While FDA Expands Bayer Approval
AstraZeneca's breast cancer drug failed a late-stage trial, while the FDA expanded approval for a Bayer lung cancer treatment and cleared an AstraZeneca COPD medication.
Sources
Every article we clustered into this story. Headlines link to the publisher.
- AstraZeneca Says Breast Cancer Pill Fails in Key Study Bloomberg.com ·
- STAT+: FDA expands Bayer lung cancer drug approval STAT
- STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon STAT
- STAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more STAT
- STAT+: FDA approves AstraZeneca breast cancer drug STAT
- STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies STAT
In this story
- AstraZeneca
- FDA